High Vista Strategies LLC Chinook Therapeutics, Inc. Transaction History

High Vista Strategies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $494,975 - $1.02 Million	26,526 Added 53.59%	76,021 $2.92 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $634,463 - $931,431	-34,056 Reduced 40.76%	49,495 $1.3 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $572,874 - $764,596	32,717 Added 64.36%	83,551 $1.64 Million
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $213,312 - $318,528	-16,943 Reduced 25.0%	50,834 $889,000
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $814,679 - $1.13 Million	67,777 New	67,777 $1.11 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.